Sio Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Sio Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-72,173	Closed	-$1.31M	–	78
2025 Q4	$1.31M	Hold	72,173	–	–	0.21%	56
2025 Q3	$917K	Hold	72,173	–	–	0.23%	42
2025 Q2	$360K	Buy	72,173 +715	+1%	+$3.34K	0.14%	45
2025 Q1	$572K	Hold	71,458	–	–	0.17%	45
2024 Q4	$531K	Hold	71,458	–	–	0.15%	42
2024 Q3	$679K	Hold	71,458	–	–	0.27%	29
2024 Q2	$891K	Buy	71,458 +61,307	+604%	+$795K	0.24%	39
2024 Q1	$221K	Buy	+10,151	New	+$54.7K	0.07%	47
2021 Q2	–	Sell	-192	Closed	-$1.67M	–	75
2021 Q1	$1.67M	Sell	192 -130	-40%	-$1.23M	0.34%	67
2020 Q4	$2.45M	Sell	322 -36	-10%	-$250K	0.5%	63
2020 Q3	$2.35M	Buy	358 +11	+3%	+$82.7K	0.46%	53
2020 Q2	$2.6M	Buy	+347	New	+$2.52M	0.76%	46

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Sio Capital Management's AVTX Position: Q1 2026 in Review

Sio Capital Management sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 72,173 shares — an estimated $1.31M sold.

Sio Capital Management first reported a position in AVTX in Q2 2020 and held it in 12 quarters. The position peaked at $2.6M in Q2 2020. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

Sio Capital Management reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
Sio Capital Management sold 72,173 Avalo Therapeutics shares in Q1 2026, an estimated $1.31M.
Sio Capital Management first reported a position in Avalo Therapeutics in Q2 2020 and held it in 12 quarters.
Sio Capital Management's Avalo Therapeutics position peaked at $2.6M in Q2 2020.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Sio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.